Clinical Trials Logo

Diffuse Parenchymal Lung Disease clinical trials

View clinical trials related to Diffuse Parenchymal Lung Disease.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03101397 Active, not recruiting - Clinical trials for Diffuse Parenchymal Lung Disease

The Clinical Value of Serum KL-6 Changes on Evaluating Disease Development in Different Diffuse Parenchymal Lung Disease

Start date: February 2013
Phase: N/A
Study type: Observational

Diffuse Parenchymal Lung Disease(DPLD) is a chronic progressive fibrosis lung disease that with a highly variable clinical process.Krebs von den Lungen-6 (KL-6) is a high-molecular-weight glycoprotein, classified as human MUC1 mucin, that is produced mainly by regenerating type II pneumocytes.Serum levels of KL-6 have been shown to be elevated in patients with DPLD and could predict progress, but unaware of the differential threshold. The objective of this study was to perspectively and sequentially monitor serum KL-6 levels in patients with different DPLD,then analyze its clinical value and find the differential threshold.